Month: September 2026

User Survey Demonstrates High Satisfaction of the LIBERTY System

Expansion of Sales Footprint Expands to Western U.S. as Company Secures First California Customer

HINGHAM, Mass., Sept. 25, 2026 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), announced that it highlighted the continuation of its commercial and growth strategy during an analyst meeting held in New York City on Thursday, September 24, 2026. The Company also highlighted select results from a user survey, available on the Company’s website, conveying high satisfaction with the system.

Key Topics Discussed:

• Expansion of the U.S. footprint is continuing, and the Company is on track to have 12 sales territories by the end of the year, to accelerate growth and support the Company’s first customer in California and its expansion in North Carolina.
• The Company’s commercial strategy has evolved to engage Value Analysis Committee (VAC) process earlier, a four-to-six-month process based on the Company’s current experience, to gain widespread access to hospital systems. The Company believes this approach will accelerate adoption of the LIBERTY System across healthcare systems with multiple hospitals. The Company is now engaged with the VAC at multiple health systems.
• Hired three additional Area Sales Managers and an additional Regional Sales Director to focus on new sales territories and expand west.
• The Company continues to advance and focus on operating efficiencies, such as adding a second manufacturing line and moving to more efficient manufacturing processes, which the Company expects will result in positive gross margins in 2027.
• Potential expansions to certain international markets, including in Asia and the Middle East, where the Company can leverage its FDA clearance, are in advanced stages, while the Company continues its engagement with regulatory bodies to support future CE mark approval which is expected in late Q4 2026 or early Q1 2027.

LIBERTY is the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, and it is designed for precise vascular navigation while aiming to reduce radiation exposure and physical strain.

About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot’s LIBERTY® Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency and safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care.

Learn more at www.microbotmedical.com and connect on LinkedIn and X.

Safe Harbor

Statements to future financial and/or operating results, future adoption of products, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,” “intends,” “may,” “might,” “possible,” “potential,” “predicts,” “projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the commercialization of the LIBERTY^® Endovascular Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical^® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical^® disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Contacts:
IR@microbotmedical.com
Media@microbotmedical.com

Six oral presentations and two posters will highlight Decipher’s prognostic and predictive value in identifying patients’ risk of progression and likelihood of benefiting from treatment intensification

SOUTH SAN FRANCISCO, Calif., Sept. 25, 2026 (GLOBE NEWSWIRE) — Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that eight studies leveraging its Decipher Prostate Genomic Classifier test and whole-transcriptome data will be presented at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting. The conference will take place September 26–30 in Boston.

The presentations include analyses from Phase II and III clinical trials, Genomic Research for Intelligent Discovery (GRID) research, and national real-world studies. Together, they examine Decipher’s prognostic value in assessing disease risk and predictive value in identifying which patients may benefit from treatment intensification, including adding androgen-deprivation therapy (ADT) to radiation.

“The breadth of research being presented at ASTRO underscores the growing role of genomic information in helping clinicians navigate complex prostate cancer treatment decisions,” said Elai Davicioni, Ph.D., Veracyte’s medical director for Urology. “These presentations demonstrate how elucidating the molecular components of tumor biology may help personalize treatment decisions for patients across different stages of disease.”

The following Decipher-focused studies will be presented at ASTRO 2026:

Oral Presentations

• Title: Evaluation of PAM50 Molecular Subtypes in Post-Prostatectomy Salvage Radiotherapy: An NRG Oncology-RTOG 0534 Analysis
  Presenter: Shuang Zhao, M.D., M.S.E.
  Abstract: 6
  Date/Time: Sunday, September 27, 1:30–1:40 p.m. ET
  Location: Grand Ballroom
• Title: The Role of Docetaxel In Addition to Salvage Radiation and Androgen Deprivation In Men with High Risk Prostate Cancer Post-Prostatectomy: Results of NRG GU002
  Presenter: Mark Hurwitz, M.D., FASTRO
  Abstract: 250
  Date/Time: Tuesday, September 29, 12:40–12:50 p.m. ET
  Location: Room 210
• Title: Genomic Stratification of Benefit From Short-Term Androgen Deprivation With Dose-Escalated Radiotherapy in Intermediate-Risk Prostate Cancer: An Ancillary Study of RTOG/NRG 0815
  Presenter: Angela Jia, M.D., Ph.D.
  Abstract: 312
  Date/Time: Tuesday, September 29, 3:55– 4:05 p.m. ET
  Location: Room 210
• Title: Multi-institutional Transcriptomic Characterization of Radiorecurrent Prostate Cancer and Prognostic Biomarkers After Salvage Re-irradiation in the F-SHARP Clinical Trial
  Presenter: Abhishek Solanki, M.D., M.S.
  Abstract: 314
  Date/Time: Tuesday, September 29, 4:15–4:25 p.m. ET
  Location: Room 210
• Title: Long-Term Transcriptomic Analysis of NRG/RTOG 9601: A Phase 3 Study of Salvage Radiotherapy for Prostate Cancer with or without Anti-Androgen Therapy
  Presenter: Krishnan Patel, M.D.
  Abstract: 315
  Date/Time: Tuesday, September 29, 4:25–4:35 p.m. ET
  Location: Room 210

Quick-Pitch Presentation

• Title: Real-World Evidence across Prostate RT Modalities: Utilization Shifts, Toxicity and BCR in Genomic Classifier Scored Patients
  Presenter: Thomas Kole, M.D., Ph.D.
  Abstract: 1166
  Date/Time: Tuesday, September 29, 5:35–5:40 p.m. ET
  Location: Room 205

Poster Presentations

• Title: Preoperative Biopsy Decipher Prostate Genomic Classifier Predicts Earlier Secondary Radiotherapy After Radical Prostatectomy in National Real-World Data
  Presenter: Thomas Kole, M.D., Ph.D.
  Abstract: 3297
  Date/Time: Sunday, September 27, 2:15–3:30 p.m. ET
  Location: Poster Hall, Exhibit Hall A
• Title: Association of 22-Gene Genomic Classifier with ADT Use with Secondary Radiotherapy: A National Real-World Analysis
  Presenter: Andrew Barsky, M.D.
  Abstract: 3226
  Date/Time: Tuesday, September 29, 2:15–3:30 p.m. ET
  Location: Poster Hall, Exhibit Hall A

Additional information is available through the ASTRO 2026 Annual Meeting program.

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company with a vision to transform cancer care for patients around the world. The company’s molecular tests assess the unique biology of each patient’s tumor to help clinicians answer essential questions about cancer care. Veracyte’s Diagnostics Platform combines broad genomic and clinical data, advanced bioinformatics and AI, and a powerful evidence-generation engine to support continued innovation and pipeline development. The company’s portfolio includes the Afirma® Genomic Sequencing Classifier test, Decipher® Bladder Genomic Classifier test, Decipher® Prostate Genomic Classifier test, Prosigna® Breast Risk of Recurrence test, and the TrueMRD™ Monitoring Test for MIBC. For more information, visit Veracyte’s website or follow the company on LinkedIn or X (Twitter).  

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including but not limited to statements regarding the potential role of genomic information in helping identify which patients may benefit from treatment intensification and helping clinicians navigate prostate cancer treatment decisions and personalize treatment decisions for patients across different stages of disease. Forward-looking statements can be identified by words such as “anticipate,” “believe,” “expect,” “may,” “potential,” “will,” and similar expressions. Actual results may differ materially from those expressed or implied by these statements due to risks and uncertainties described under the caption “Risk Factors” in Veracyte’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this release, and Veracyte disclaims any obligation to update them except as required by law.

Veracyte, the Veracyte logo and Decipher are registered trademarks of Veracyte, Inc. and its subsidiaries in the United States and selected countries.

Investors: 
Kelly Gura  
investors@veracyte.com

Media: 
Molly Cornbleet 
media@veracyte.com 
+1 650-351-8780